Name: Targeted Therapy Delays Growth for IDH-Mutant Glioma
Uploaded: 2023-06-06
Duration: 2 min 10 s
Description: Neuro-oncologist Ingo Mellinghoff, MD, FACP discusses how his research has led to a new targeted therapy for IDH-mutant glioma – and details how this may mark a paradigm shift in therapeutic options for patients with brain tumors.

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

Sloan Kettering Institute
Research
- - Changing how the world understands and treats cancer
    Our scientists pursue every aspect of cancer research—from exploring the biology of genes and cells, to developing immune-based treatments, uncovering the causes of metastasis, and more.
- - Programs & Centers
  - Sloan Kettering Institute
    Pursuing basic and translational research across 9 programs and 100+ labs
  - Memorial Hospital research
    Focusing on clinical cancer research and population health
  - Human Oncology & Pathogenesis Program (HOPP)
    Bridging the lab and the clinic through translational research
  - Collaborative research centers
    Fostering interdisciplinary collaborations between laboratory scientists and clinicians
  - Extramural collaborations
    Partnering with other academic and research institutions
- - Research at MSK
  - Our research impact
  - Research topics
  - Core facilities & resources
    Offering state-of-the-art resources for our researchers
  - Find a researcher or lab
  - Education & training programs
Education & Training
- - Training the next generation of clinicians and scientists
    Our highly-specialized educational programs shape leaders to be at the forefront of cancer care and research.
Careers
MSK Direct
Locations & Language
In the U.S.
Outside of the U.S.

Make an Appointment
Back
Make an Appointment
- - We’re here for you.
    Make an appointment
    New patient
    Current patient
    Speak to a care advisor
    Adults: 800-525-2225
    Available 24 hours a day, 7 days a week
    Children & Teens: 833-MSK-KIDS
    Monday through Friday, 9 a.m. to 5:30 p.m. (Eastern time)
Learn About Cancer & Treatment
Back
Learn About Cancer & Treatment
- - We treat every type of cancer, including the most important one: yours.
    With cancer, where you get treated first matters. From diagnosis to treatment, our experts provide the care and support you need, when you need it.
- - Adults
  - Cancers & conditions
  - Risk assessment & screening
  - Diagnosis & treatment
  - Clinical trials
  - Children & Teens
  - Cancers & conditions
  - Diagnosis & treatment
  - Clinical trials
- - Support, Services & Programs
  - For adults
  - For children & teens
  - For caregivers
  - Adolescents & young adult (AYA) program
  - Patient & caregiver education library
  - Cancer News & Discoveries
  - Read the latest
  - Sign up for our newsletter
For Physicians
Back
For Physicians
- - Partner with us to treat your patient’s cancer.
    Refer a patient
    CALL OUR DEDICATED CLINICIAN ACCESS NUMBER
    646-677-7440
    Monday through Friday, 8 a.m. to 6 p.m. (Eastern time)
- - Clinical Resources
  - Our doctors
  - Physician relations
  - Clinical updates & insights
  - Prediction tools
  - Clinical trials
  - Continuing medical education (CME)
About Us
Back
About Us
- - Our mission: Ending cancer for life.
    Memorial Sloan Kettering was founded in 1884, and today is a world leader in patient care, research, and educational programs.
- - About Us
  - Our mission, vision & core values
  - Leadership
  - History
  - Equality, diversity & inclusion
  - Annual report
  - Give to MSK
  - For the Media
  - Media inquiries
  - Press Releases
  - Newsroom
- - Have Questions?
  - Contact us
  - Plan Your Visit
  - Explore our locations
  - Directions
  - Visitor policy
Patient Portal: MyMSK
Donate Now
- Sloan Kettering Institute
- Research
  Back
  Research
  - Programs & Centers
    Sloan Kettering Institute
    Pursuing basic and translational research across 9 programs and 100+ labs
    Memorial Hospital research
    Focusing on clinical cancer research and population health
    Human Oncology & Pathogenesis Program (HOPP)
    Bridging the lab and the clinic through translational research
    Collaborative research centers
    Fostering interdisciplinary collaborations between laboratory scientists and clinicians
    Extramural collaborations
    Partnering with other academic and research institutions
  - Research at MSK
    Our research impact
    Research topics
    Core facilities & resources
    Offering state-of-the-art resources for our researchers
    Find a researcher or lab
    Education & training programs
- Education & Training
  Back
  Education & Training
  - For Healthcare
    Graduate medical education (GME)
    Medical student opportunities
    Continuing medical education (CME)
    Continuing nursing education (CNE)
    Academic departments & divisions
    Explore all programs
  - For Research
    Postdoctoral training
    Gerstner Sloan Kettering Graduate School of Biomedical Sciences
    PhD & MD/PhD programs
    Explore all programs
- Careers
- MSK Direct
- Locations & Language
  Back
  Locations & Language
  In the U.S.
  English
  Español
  Pусский
  Outside of the U.S.
  العَرَبِيَّة
  Deutsch
  English
  Español
  한국어
  עִבְרִית
  Italiano
  Portugês
  Pу́сский
  Türkçe
  中文

VIDEO | 02:10

Neuro-oncologist Ingo Mellinghoff, MD, FACP discusses how his research has led to a new targeted therapy for IDH-mutant glioma – and details how this may mark a paradigm shift in therapeutic options for patients with brain tumors.

Changing how the world understands and treats cancer

Training the next generation of clinicians and scientists

We’re here for you.

Make an appointment

Speak to a care advisor

We treat every type of cancer, including the most important one: yours.

Partner with us to treat your patient’s cancer.

CALL OUR DEDICATED CLINICIAN ACCESS NUMBER

Our mission: Ending cancer for life.

In the U.S.

Outside of the U.S.